You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors

Authors

  • Qian Tao Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Nian Liu Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Jie Wu Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Jing Chen Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Xiang Chen Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Cong Peng Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles

Citation

Tao Q, Liu N, Wu J, et al
Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors
Journal for ImmunoTherapy of Cancer 2024;12:e008554. doi: 10.1136/jitc-2023-008554
Online issue publication 
March 11, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.